Josh Himmelstern

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Red Canary, a top managed detection and response platform that investigate threats while streamlining workflows through automated remediation, on its acquisition by Zscaler (Nasdaq: ZS).

Cooley advised DataStax, an artificial intelligence (AI) and data solution provider, on its acquisition by IBM (NYSE: IBM), a provider of global hybrid cloud and AI solutions and consulting expertise.

Cooley advised Machinify, a provider of artificial intelligence-powered software transforming healthcare payments, on its definitive agreement to be acquired by New Mountain Capital.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.